Want to create an interactive transcript for this episode?
Podcast: Business Daily
Episode: Weight-loss drugs. Who pays?
Description: GLP-1 weight-loss drugs such as Ozempic, Wegovy, Zepbound and Mounjaro are reshaping the treatment of obesity — and transforming the global pharmaceutical market.Originally developed to treat type-2 diabetes, these injectable medicines — including semaglutide and tirzepatide — are now widely prescribed for weight loss, with growing evidence they can also reduce the risk of heart disease and stroke.But in the United States, access to GLP-1 drugs often depends on insurance coverage — and on who can afford to pay.In this first episode of a three-part Business Daily series on the global weight-loss economy, Sam Fenwick...